Clinical High Risk for Psychosis (CHR)
1
Pipeline Programs
3
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
2027
2028
2029
2030
2031
Jazz PharmaceuticalsCannabidiol
Monument TherapeuticsMT1988 Low Dose
Angeles TherapeuticsCognitive training
Clinical Trials (3)
Total enrollment: 790 patients across 3 trials
Stratification and Treatment in Early Psychosis Study - PROMOTE
Start: May 2026Est. completion: Dec 2031586 patients
Phase 3Not Yet Recruiting
A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis
Start: Mar 2026Est. completion: Oct 2027150 patients
Phase 1/2Recruiting
Interventions for Clinical High Risk Youth in Tunisia
Start: Sep 2023Est. completion: Aug 202654 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 790 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.